Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 May-Jun;8(3):128-32.

Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB

Amanda R Moraska  1 , Pamela J Atherton, Daniel W Szydlo, Debra L Barton, Philip J Stella, Kendrith M Rowland Jr, Paul L Schaefer, James Krook, James D Bearden, Charles L Loprinzi
Affiliations
Clinical Trial

Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB

Amanda R Moraska et al. J Support Oncol. 2010 May-Jun.

Abstract

Hot flashes are a complication of androgen deprivation therapy for prostate cancer. A phase III study showed that use of low-dose gabapentin was well tolerated and moderately decreased the frequency of hot flashes due to androgen deprivation therapy when taken for 4 weeks. The current study, an open-label continuation of the randomized study, examined the efficacy and toxicity of gabapentin when taken for (an additional) 8 weeks. Patients were allowed to start, or continue, gabapentin and to titrate the dose to maximum efficacy, up to 900 mg/d. They were asked to complete a hot flash diary daily and keep weekly logs of toxicity, satisfaction with hot flash control, and quality of life. The moderate reduction in hot flash frequency and severity in the randomized phase of the study appeared to be maintained during this continuation phase. Men originally receiving the placebo or lowest dose of gabapentin (300 mg/d) had improved hot flash control relative to that at the end of the randomized phase. Minimal adverse effects were reported. These findings suggest that low-dose gabapentin is moderately efficacious for at least 12 weeks of hot flash treatment in men undergoing androgen deprivation therapy for prostate cancer and seems to be well tolerated. (NCT00028572)

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean gabapentin doses over time, segregated by the initial 4 study arms.
Figure 2
Figure 2
Mean hot flash scores over time, segregated by the initial 4 study arms.
Figure 3
Figure 3
Mean hot flash frequencies over time, segregated by the initial 4 study arms.
See this image and copyright information in PMC

References

    1. Schow DA, Renfer LG, Rozanski TA, et al. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J. 1998;91:855–857. - PubMed
    1. Charig CR, Rundle JS. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology. 1989;33:175–178. - PubMed
    1. Clark JA, Wray N, Brody B, et al. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med. 1997;45:1299–1309. - PubMed
    1. Loprinzi C, Goldberg RM, O'Fallon JR, et al. Transdermal clonidine for ameliorating postorchiectomy hot flashes. J Urol. 1993;151:634–636. - PubMed
    1. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331:347–352. - PubMed

Publication types

MeSH terms

Associated data